A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Bibliographic Data

ID15718598
AuthorsSaeed Alzabali (0000-0001-8815-4765, King Fahd Medical City, corresponding author), Sawsan Albatati (King Fahd Medical City), Khawla A Rahim (King Fahd Medical City), Khawla Rahim (Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia), Hassan Faqeehi (King Fahd Medical City), Abubaker Osman (King Fahd Medical City), Abdulaziz A Bamhraz (McMaster University), Abdulaziz Bamhraz (Division of Pediatric Nephrology, Children’s Hospital-McMaster University, Hamilton, ON L8N 3Z5, Canada), Mohammed A Saleh (0000-0003-0321-287X, King Fahd Medical City), Jameela A Kari (0000-0001-7628-8926, King Abdulaziz University), Majed Aloufi (0000-0001-7953-4539, Riyadh Armed Forces Hospital), Loai Eid (Dubai Hospital), Haydar A Nasser (0000-0002-9321-7641, King Fahad Hospital Jeddah), Haydar Nasser (Pediatric Nephrology Department, King Fahad Military Hospital, Jeddah 21589, Saudi Arabia), Abubakr Imam (0000-0001-5297-6177, Pediatric Nephrology and Hypertension, Sidra Medicine, Doha P.O. Box 26999, Qatar), Entesar AlHammadi (Dubai Health Authority), Omar Alkandari (Mubarak Al Kabeer Hospital), Mohamed S Al Riyami (0000-0003-3698-5609, Royal Hospital), Sidharth Kumar Sethi (0000-0002-1516-3393, Medanta The Medicity), Christoph Licht (0000-0003-4168-3277, Hospital for Sick Children), Khalid Alhasan (0000-0002-4291-8536, King Saud University), Abdulkarim Alanazi (King Fahd Medical City)
Year2022
Volume9
Issue11
Pages1734-1734
Publication date2022-11-11
Open AccessYes
TypeARTICLE
VenueChildren (JOURNAL)
Journal identifiersISSN: 2227-9067 • E-ISSN: 2227-9067
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/children9111734
PMID36421183
OpenAlexW4308970537
LanguageEN
References cited18

The discontinuation of eculizumab in patients with aHUS is not without risk; it can result in HUS recurrence. Eculizumab discontinuation can be performed with close monitoring of the patients. It is essential to assess risk the factors for relapse before eculizumab discontinuation, in particular in children with a positive complement variant and any degree of residual CKD, as HUS relapse may lead to additional loss of kidney function. Resuming eculizumab promptly after relapse is effective in most patients

Antibody · Atypical hemolytic uremic syndrome · Complement system · Dialysis · Discontinuation · Disease · Eculizumab · Kidney disease · Retrospective cohort study · Thrombotic microangiopathy · Adenosine and Purinergic Signaling · Complement system in diseases · Medicine · Renal Diseases and Glomerulopathies · Immunology · Internal Medicine · Pediatrics

Tools

Open DOIOpen Access